Send the following on WhatsApp
Continue to Chathttps://www.zonebourse.com/cours/action/INNOCARE-PHARMA-LIMITED-105526513/actualite/InnoCare-Pharma-Limited-annonce-l-approbation-de-l-essai-clinique-de-l-inhibiteur-de-BCL2-ICP-248-en-46156884/?utm_source=whatsapp&utm_medium=social&utm_campaign=share